Axenfeld-Rieger Syndrome Associated with Congenital Glaucoma and Cytochrome P4501B1 Gene Mutations.
Developmental anomalies of the ocular anterior chamber angle may lead to an incomplete development of the structures that form the conventional aqueous outflow pathway. Thus, disorders that present with such dysfunction tend to be associated with glaucoma. Among them, Axenfeld-Rieger (ARS) malformation is a rare clinical entity with an estimated prevalence of one in every 200,000 individuals. The changes in eye morphogenesis in ARS are highly penetrant and are associated with 50% risk of development of glaucoma. Mutations in the cytochrome P4501B1 (CYP1B1) gene have been reported to be associated with primary congenital glaucoma and other forms of glaucoma and mutations in pituitary homeobox 2 (PITX2) gene have been identified in ARS in various studies. This case was negative for PITX2 mutations and compound heterozygote for CYP1B1 mutations. Clinical manifestations of this patient include bilateral elevated intraocular pressure (>40 mmHg) with increased corneal diameter (>14 mm) and corneal opacity. Patient also had iridocorneal adhesions, anteriorly displaced Schwalbe line, anterior insertion of iris, broad nasal bridge and protruding umbilicus. This is the first study from north India reporting CYP1B1 mutations in Axenfeld-Rieger syndrome with bilateral buphthalmos and early onset glaucoma. Result of this study supports the role of CYP1B1 as a causative gene in ASD disorders and its role in oculogenesis.
Tanwar
Mukesh
M
Laboratory for Molecular Reproduction and Genetics, Department of Anatomy, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India.
Dada
Tanuj
T
Dada
Rima
R
Ophthalmic Genet. 2004 Dec;25(4):257-70
15621878
Trends Genet. 2000 May;16(5):198-200
10782110
Hum Mol Genet. 1997 Apr;6(4):641-7
9097971
Am J Med Genet. 1978;2(3):307-18
263445
Invest Ophthalmol Vis Sci. 2002 Jun;43(6):1820-7
12036985
J Med Genet. 1992 Apr;29(4):256-8
1583647
Nucleic Acids Res. 2002 Sep 1;30(17):3894-900
12202775
Am J Hum Genet. 1998 Mar;62(3):573-84
9497261
J Med Genet. 2001 May;38(5):324-6
11403040
Mol Vis. 2009 Jun 13;15:1200-9
19536304
Mol Vis. 2006 Dec 01;12:1448-60
17167399
Biofactors. 1999;10(2-3):85-9
10609867
J Biochem. 1993 Nov;114(5):652-7
8113216
Am J Ophthalmol. 2000 Jul;130(1):107-15
11004268
Gene. 2004 Oct 13;340(2):251-60
15475166
Drug Metab Dispos. 2000 Mar;28(3):315-22
10681376
Mol Vis. 2003 Feb 18;9:43-8
12592227
J Clin Pediatr Dent. 2005 Fall;30(1):83-8
16302606
Nat Protoc. 2009;4(7):1073-81
19561590
Am J Hum Genet. 1999 Sep;65(3):656-63
10441571
Mol Vis. 2007 Apr 02;13:511-23
17417613
Hum Mol Genet. 2001 Mar 15;10(6):591-7
11230178
Am J Ophthalmol. 2003 Mar;135(3):368-75
12614756
Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4200-3
14507861
Nat Genet. 1998 Jun;19(2):140-7
9620769
Nucleic Acids Res. 2003 Jul 1;31(13):3812-4
12824425
Carcinogenesis. 1992 Oct;13(10):1789-94
1423839
Trans Am Ophthalmol Soc. 1983;81:736-84
6676983
Br J Ophthalmol. 2004 May;88(5):720-1
15090434
Mol Vis. 2005 Jan 21;11:66-70
15682044
Am J Hum Genet. 1996 Sep;59(3):613-9
8751862
Arch Ophthalmol. 1966 Mar;75(3):307-18
5948260
Pharmacogenet Genomics. 2008 Aug;18(8):665-76
18622259
Am J Hum Genet. 2002 Feb;70(2):448-60
11774072
Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2211-6
11527932
Mol Vis. 2006 May 16;12:506-10
16735991
Nat Genet. 1994 Feb;6(2):168-73
8162071
Mol Endocrinol. 1991 Sep;5(9):1203-14
1663211
J Glaucoma. 2001 Aug;10(4):354-7
11558822
J Med Genet. 1999 Apr;36(4):290-4
10227395
Br J Ophthalmol. 1991 Oct;75(10):591-7
1954207
Mol Vis. 2006 May 22;12:523-31
16735994
Genomic Med. 2008 Jan;2(1-2):23-32
18716917
Mol Vis. 2009 Dec 30;15:2926-37
20057908
Am J Hum Genet. 1998 Feb;62(2):325-33
9463332
Ophthalmic Genet. 2004 Mar;25(1):57-62
15255117
Am J Ophthalmol. 1981 Mar;91(3):347-50
7211991